James J. Burns & Company LLC Acquires 11,000 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

James J. Burns & Company LLC lifted its stake in Wave Life Sciences Ltd. (NASDAQ:WVE) by 11.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 111,111 shares of the company’s stock after purchasing an additional 11,000 shares during the period. James J. Burns & Company LLC owned 0.07% of Wave Life Sciences worth $1,374,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its holdings in Wave Life Sciences by 126.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 54,267 shares of the company’s stock worth $671,000 after purchasing an additional 30,276 shares during the period. Moody Aldrich Partners LLC raised its stake in Wave Life Sciences by 31.5% during the 4th quarter. Moody Aldrich Partners LLC now owns 398,475 shares of the company’s stock worth $4,929,000 after buying an additional 95,413 shares during the period. KBC Group NV bought a new position in Wave Life Sciences during the fourth quarter worth about $67,000. SG Americas Securities LLC grew its stake in Wave Life Sciences by 46.1% in the fourth quarter. SG Americas Securities LLC now owns 53,419 shares of the company’s stock valued at $661,000 after acquiring an additional 16,856 shares during the period. Finally, Kraematon Investment Advisors Inc. increased its holdings in shares of Wave Life Sciences by 24.3% in the fourth quarter. Kraematon Investment Advisors Inc. now owns 19,885 shares of the company’s stock worth $246,000 after acquiring an additional 3,885 shares in the last quarter. 89.73% of the stock is owned by institutional investors and hedge funds.

Wave Life Sciences Stock Performance

NASDAQ WVE opened at $11.86 on Tuesday. The business has a fifty day moving average price of $13.11 and a two-hundred day moving average price of $10.42. Wave Life Sciences Ltd. has a fifty-two week low of $3.50 and a fifty-two week high of $16.74.

Insider Buying and Selling

In other news, CEO Paul Bolno sold 51,234 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $14.32, for a total value of $733,670.88. Following the completion of the sale, the chief executive officer now owns 217,351 shares in the company, valued at $3,112,466.32. This represents a 19.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Chris Francis sold 36,000 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $576,000.00. The disclosure for this sale can be found here. Insiders sold 137,234 shares of company stock valued at $2,059,671 over the last quarter. Insiders own 29.10% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Truist Financial boosted their price objective on Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. Raymond James raised shares of Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $13.00 to $22.00 in a research report on Wednesday, October 16th. Leerink Partners upped their target price on shares of Wave Life Sciences from $20.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. JPMorgan Chase & Co. lifted their price target on Wave Life Sciences from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.22.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.